AmacaThera Announces Close of Oversubscribed Series A Financing to Advance a Novel Post-Operative, Nonopioid Pain Therapy in Clinical Trials

– AmacaThera announced the close of an oversubscribed $10.3m Series A financing to support development of AMT-143, the company’s lead clinical asset, and pipeline expansion.
– The Series A round was led by Lumira Ventures and includes a global investor syndicate of existing investors, Viva BioInnovator and Sprout BioVentures, as well as new investors, BDC Capital Women in Technology (WIT) Venture Fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures, and MaRS IAF.